Mefloquine: strengthened warnings on neuropsychiatric side effects

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
14 November 2013

Abstract

A recent review of the prescribing information has led to strengthened warnings and new measures to help minimise risks. To minimise the risk of these adverse reactions, mefloquine must not be used for chemoprophylaxis in patients with active or a history of psychiatric disturbances such as depression, anxiety disorders, schizophrenia, or other psychiatric disorders.